Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Status:
Completed
Trial end date:
2002-07-15
Target enrollment:
Participant gender:
Summary
To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel
given in doses titrated to effect in acromegalic patients previously treated or not with
somatostatin analogues.